Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Jan 26;2(1):35-39.
doi: 10.2991/chi.d.200116.001. eCollection 2020 Mar.

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma

Kristian T Andersen  1 , Maja Hinge  1 , Agoston Gyula Szabo  1 , Erik Segel  2 , Tina Ormstrup  3 , Paw C Holdgaard  4 , Niels Pallisgaard  5 , Gitte Kerndrup  6 , Torben Plesner  1
Affiliations

Safety and Efficacy of Doxorubicin, Cyclophosphamide, Bortezomib, Dexamethasone and Lenalidomide Followed by Bortezomib Consolidation as First-Line Therapy in Patients with Newly Diagnosed Multiple Myeloma

Kristian T Andersen et al. Clin Hematol Int. .
No abstract available

Keywords: Clinical trial; First line therapy; Hematology; Multiple myeloma.

PubMed Disclaimer

Conflict of interest statement

None of the authors have conflicts of interest to report.

Figures

Figure 1
Figure 1
(A) Kaplan-Meyer curve illustrating overall survival for the intention to treat population. (B) Kaplan-Meyer curve illustrating progression-free survival for the intention to treat population. (C) Kaplan-Meyer curve illustrating progression-free survival 2 for the intention to treat population.
See this image and copyright information in PMC

References

    1. Chakraborty R, Muchtar E, Kumar S, et al. The impact of induction regimen on transplant outcome in newly diagnosed multiple myeloma in the era of novel agents. Bone Marrow Transplant. 2017;52:34–40. doi: 10.1038/bmt.2016.214. - DOI - PubMed
    1. Kumar SK, Dispenzieri A, Lacy MQ, et al. Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients. Leukemia. 2014;28:1122–8. doi: 10.1038/leu.2013.313. - DOI - PMC - PubMed
    1. Kyle RA, Child JA, Anderson K, et al. Criteria for the classification of monoclonal gammopathies, multiple myeloma and related disorders: a report of the International Myeloma Working Group. Br J Haematol. 2003;121:749–57. doi: 10.1046/j.1365-2141.2003.04355.x. - DOI - PubMed
    1. Reeder CB, Reece DE, Kukreti V, et al. Cyclophosphamide, bortezomib and dexamethasone (CyBorD) induction for newly diagnosed multiple myeloma: high response rates in a phase II clinical trial. Leukemia. 2009;23:1337. doi: 10.1038/leu.2009.26. - DOI - PMC - PubMed
    1. Einsele H, Liebisch P, Langer C, et al. Velcade, Intravenous Cyclophosphamide and Dexamethasone (VCD) induction for previously untreated multiple myeloma (German DSMM XIa Trial) Blood. 2009;114:131. doi: 10.1182/blood.v114.22.131.131. - DOI

LinkOut - more resources